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Abstract
Background: High-risk human papillomavirus (HR HPV) testing is already part of cervical cancer screening programs
in a number of countries. New tests need to be validated not only in clinical studies but also in routine screening
settings with regard to their clinical performance.
Methods: The Abbott RealTime High Risk HPV Test (RT hrHPV test) was evaluated in a random sample of 1,456
patients from a German routine screening population of 13,372 women ≥30 years of age screened primarily by
liquid-based cytology (LBC) that was complemented by 48 CIN3+ cases. Clinical sensitivities, relative specificities and
positive predictive values (PPV) for both HPV tests were determined based on histologically confirmed high-grade
cervical disease (CIN3+) as clinical outcome.
Results: HR HPV prevalence in residual LBC samples was found to be 5.4 % by the RT hrHPV test and 5.6 % by the
HR HC2 test, respectively. The Kappa-value for overall agreement between the RT hrHPV test and the HC2 assay for
detection of HR HPV was 0.87. Relative sensitivities for detection of CIN3+ in patients with abnormal cytology was
93.8 % for the RT hrHPV assay and 97.9 % for HC2 (p-value = 0.5). Relative specificities and PPVs were comparable
for both tests. The highest PPV was calculated for the specific detection of HPV16 by the RT hrHPV test (84.2 %).
The RT hrHPV test showed a reduced sensitivity for detection of HVP31-positive CIN3 + .
Conclusion: The RT hrHPV assay is as sensitive and specific in detecting severe cervical lesions in women with
abnormal cytology as the HC2 HR HPV test.
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Background
Since the introduction of opportunistic cytological
screening in Germany in 1971 the cervical cancer mor-
tality rate has notably decreased [1]. However, 4,600 new
cases and approximately 1,500 deaths due to cervical
cancer are diagnosed in Germany each year [2]. More-
over, 150,000 cases of cervical cancer precursors (CIN3)
are detected annually [3] and cervical cancer is the cause
for 1.5 % of all female cancer deaths in Germany [2]. As
persistent infection with High-Risk Human Papillomavi-
ruses (HR HPV) is a necessary risk factor for the devel-
opment of (pre)-cancer, numerous HPV tests are
nowadays commercially available [4] to be used in cer-
vical cancer screening programs [5]. However, only a
small number of these tests have been approved by the
FDA [6] with the Digene Hybrid Capture 2 High-Risk
HPV DNA test as the first one (HC2; QIAGEN Hilden,
Germany). The HC2 has been developed for the collect-
ive detection of 13 carcinogenic HPV types (16, 18, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 68) [7]. It is one of the
best validated HPV tests whose methodology is based on
nucleic acid hybridization with signal amplification for
qualitative detection of HPV-DNA within cervical
samples.
The Abbott RealTime High Risk HPV Test (RT
hrHPV) is another fully automated HPV DNA test
which is based on real-time PCR that targets the L1 re-
gion of the 13 carcinogenic HPV types 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 68 and for detection of HPV
66. The multiplex design of the assay allows HPV16 and
18 genotyping as well as the collective detection of the
12 remaining HPV types [8]. The RT hrHPV test has
been fully validated by several cross-sectional studies
that evaluated its clinical performance in referral popula-
tions [9–18]. However, to date only four screening
population-based cross sectional studies [19–22] and
one follow-up study are available [23]. The objective of
this retrospective study was the cross-sectional evalu-
ation of the RT hrHPV assay in a routine cervical cancer
screening population comprising women aged ≥ 30 years
in Germany.
Methods
The study cohort and methodology has previously been
published [24].
Study design
Briefly the study was conducted on a sample of 2,303
women of a routine screening population of 13,372
women ≥ 30 years of age living in the Hannover area of
Germany in 2011 (Fig. 1). Cervical samples were col-
lected in PreservCyt® Pap Test specimen collection
medium (Hologic) and cytology was tested within 1
week after collection in a central services laboratory
(Amedes, Bad Münder, Germany). After exclusion of in-
eligible samples, a total of 1,456 residual liquid based cy-
tology (LBC) smears from this cohort including all
samples with abnormal and ASC-US cytology results as
well as 10 % of randomly selected samples with normal
cytology results were tested by both HR HC2 and Ab-
bott RealTime High Risk HPV Test (RT hrHPV). This
collection was complemented with samples from 48 pa-
tients with CIN3+ from a separate referral cohort in
order to obtain a sufficient CIN3+ rate. HC2 tests were
Fig. 1 Study Flow Chart
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conducted in the laboratory of the Division of Experi-
mental Virology at the University Hospital in Tübingen.
RT hrHPV assays were performed in the Amedes labora-
tory within 2 weeks after collection. Samples with dis-
cordant HPV test results were genotyped by INNO-LiPA
HPV Genotyping Extra® for discrepancy analysis.
Samples were anonymized thus, participants were un-
aware of their HPV test results and colposcopy as well as
histopathology was only performed when indicated by
German standard operating procedures. Samples with a pri-
mary histology of ≥CIN2+ were independently reviewed by
up to two pathologists.
Sample collection
Sample Collection has previously been described [24].
Briefly cervical samples were collected in LBC Preserv-
Cyt® Collection medium (Hologic) using the Cervex
broom according to routine guidelines. Samples were
then centrally tested by cytology within one week of
collection.
Liquid based cytology
LBC was performed as described before [24] by the
ThinPrep® 2000 Processor (Hologic) following the manu-
facturer’s instructions. Cytology results were reported
using the Munich Nomenclature II and were translated
into The Bethesda System (TBS) ([25]; Table 1). LBC re-
sults were considered negative when the result was Pap
I/II (Normal) or Pap IIw (ASC-US); all other results
were considered positive [24].
HPV testing and genotyping
LBC samples were tested by Abbott RealTime High Risk
HPV Test (RT hrHPV) in compliance with the manufac-
turer’s instructions. All specimens included in this study
were initially tested by RT hrHPV test and subsequently
analyzed by Digene Hybrid Capture 2 High-Risk HPV
DNA (HC2) test. HC2 testing has previously been de-
scribed [24].
HPV genotyping was carried out using the INNO-
LiPA HPV Genotyping Extra® test (Fujirebio LiPA Extra)
which identifies 20 HPV genotypes classified as Group 1,
2A and 2B carcinogens (16, 18, 26, 31, 33, 35, 39, 45, 51,
52, 53, 56, 58, 59, 66, 68, 69, 70, 73, 82) and 8 low-risk
HPV or intermediate risk genotypes (6, 11, 40, 43, 44,
54, 71, 74). LiPA Extra is a line blot assay based on SPF-
10-PCR as described previously [26]. Strips were
scanned and analyzed automatically with a flatbed scan-
ner and the LiRAS software (Fujirebio).
Histology reviews
As detailed before all samples with an initial histology
result of ≥CIN2+ were reviewed by an independent ex-
ternal expert. In the case of a discrepant review reading,
a second histology review was performed. If two out of
three diagnoses were identical, the result was considered
final [24].
Statistical analysis
As described [24] statistical analysis was performed on
all samples with valid LBC, RT hrHPV and HC2 (N =
1,456) test results. To calculate the agreement between
RT hrHPV and HC2, the Cohen’s kappa value (κ) was
used. The Wilson score method was used to calculate
95 % confidence intervals (CI) for HPV prevalence.
Moreover, clinical sensitivity and relative specificity as
well as positive predictive values (PPV) and negative pre-
dictive values (NPV) were calculated according to
Cuzick et al. [20] based CIN3+ histology results.
Relative performance of the two tests was measured by
calculating the ratio of the sensitivity to the specificity.
This ratio of the sensitivity of the two tests was defined as
the True Positive rate of the first test divided by the True
Positive rate of the second test. The relative specificity on
Table 1 HPV prevalence detected by the RT hrHPV test and the HC2 test in comparison to the liquid based cytology (LBC) results
LBC RT + ve % (95 % CI) HR HC2 + ve % (95 % CI) κ (95 % CI)
Normal (Pap I/II) 5.4 % (4.2-6.9) 5.6 % (4.3-7.1) 0.78 (0.69-0.87)
ASC-US (Pap IIw) 21.4 % (12.7-33.8) 28.6 % (18.4-41.5) 0.62 (0.38-0.86)
ASC-H, AGC (Pap III) 50.0 % (28.0–72.0) 50.0 % (28.0–72.0) 1 (1.0–1.0)
LSIL, HSIL (Pap IIID) 65.1 % (59.6–70.3) 72.1 % (66.8–76.9) 0.76 (0.68–0.84)
HSIL, CIS (Pap IVa) 94.7 % (82.7–98.6) 100 % (90.8–100) 1
HSIL, CIS, Micro (IVb) 100 % (34.2–100) 100 % (34.2–100) 1
Micro, Invasive (PapV) 100 % (20.6–100) 100 % (20.6–100) 1
HSIL+ (≥Pap IVa) 95.1 % (83.9–98.7) 100 % (91.4–100) 1
AGC+ (≥Pap III) 68.0 % (62.9–72.5) 74.3 % (69.5–78.6) 0.78 (0.70–0.84)
Overall 21.4 % (19.3–23.5) 23.4 % (21.3–25.6) 0.87 (0.84–0.90)
+ve: positive; −ve: negative; +: and worse
95 % CI for HPV prevalence were calculated using the Wilson Score method
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the other hand, is dependent of prevalence, and was
expressed as Spec(RT hrHPV)/Spec(HC2) = (0.818-Preva-
lence)/(0.800 - Prevalence). The delta method was used to
determine confidence intervals. A full description of this
method has previously been published [24]. Statistical ana-
lysis of the relative sensitivity and specificity was calcu-
lated using the statistics software package R version 3.0.2.
Results
Of 2,303 overall specimens a total of 847 samples had to
be excluded from the analysis either because they returned
unsatisfactory cytology results (n = 196), because they
could not be analyzed by all three tests due to insufficient
material (n = 547) or because study participants were
younger than 30 years of age (n = 104). The 1,456
remaining specimens were tested by both RT hrHPV and
HC2 (Fig. 1). 358 of these samples had an abnormal
cytology result (Pap ≥ III; ≥ASC-H) 56 were classified as
ASC-US (Pap IIw) and 1,042 women had normal cytology
results (Pap I/II) (Table 1 and 2). Colposcopy and histo-
pathology on biopsies was only performed on 33 patients
with abnormal cytology results independent of the HPV
test results. A total of 9 CIN2 cases were identified by
review histopathology. The remaining 24 biopsies were
< CIN2. In order to obtain a higher CIN3+ rate, a total of
48 CIN3+ cases were added to the cohort.
HPV prevalence and type distribution
Concordant HPV DNA test results were obtained from
1,391 of 1,456 LBC samples (Table 2). Thus the overall
percentage of agreement was 95.5 % and the Kappa coef-
ficient was κ = 0.87 (95%CI: 0.84-0.90). The overall HR
HPV positivity rate determined by HC2 was high with
23.4 % and 21.4 % by RT hrHPV. In the cytology normal
group (Pap I/II) HR HPV was detected in 5.4 % of the
specimens by RT hrHPV and in 5.6 % using the HC2
assay, respectively (Table 1 and Fig. 2). In the ASC-US
category, HPV prevalence was 21.4 % for RT hrHPV and
28.6 % for HC2. In samples with abnormal cytology HR
HPV was detected in 50 % of the LBC specimens classi-
fied as ASC-H, AGC (Pap III) by RT hrHPV as well as
HC2, compared to 65.1 % versus 72.1 %, respectively, in
the LSIL, HSIL (Pap IIID) category and 94.7 % (RT
hrHPV) versus 100 % (HC2) in category HSIL, CIS (Pap
IVa). HPV prevalence in women with glandular abnor-
mal cytology (Pap III+; AGC+) was 68 % detected with
RT hrHPV and 71.3 % with HC2 test.
Cohen’s Kappa Coefficients (κ) were calculated to
measure the agreement of RT hrHPV and HC2 within
the different LBC categories (Table 1). Kappa values (κ)
were excellent for normal (Pap I/II) samples (κ = 0.78)
and all abnormal LBC categories ≥ LSIL (≥Pap III κ =
0.78). For ASC-US (Pap IIw) specimens the agreement
was fair (κ = 0.62).
A total of 65 discordant samples were detected be-
tween the RT hrHPV and HC2 (Table 3). 47 discrepant
samples (72.3 %) were RT hrHPV-negative and HC2-
positive compared to only 18 samples (27.7 %) with
HC2-negative and RT hrHPV-positive test results. The
majority of discordant results was detected in specimens
with ASC-H (PapIII 14.3 %) cytology results followed by
the LSIL, HSIL (Pap IIID, 10.3 %) and the normal (Pap
I/II, 2.3 %) cytology categories. All deviant samples
(n = 65) were genotyped using the INNO-LiPA HPV
Genotyping Extra test in order to identify false positive
or false negative samples (Table 3). As a result we re-
solved 5 RT hrHPV-negative and 7 HC2-negative sam-
ples as true negatives. While four samples were
inadequate for LiPA genotyping, all remaining samples
(n = 49) were HPV DNA positive.
In detail one sample missed by HC2 contained a non-
target type of the HC2 assay and a total of 9 specimens
(50 %) were false-negative by HC2. However, none of
the samples missed by HC2 had a histology result of
CIN3+. Interestingly, the HC2 assay detected HPV DNA
in 18 RT hrHPV-negative samples, which contained
non-target types of either HPV DNA test including 11
cases of HPV 53.
In contrast 18 discordant samples (38.3 %) with nega-
tive RT hrHPV and positive HC2 test results were non-
target types of the RT hrHPV test (including 2 HPVX








RT Positive 293/20.1 % 18/1.2 % 311/21.4 %
Negative 47/3.3 % 1,098/75.4 % 1,145/78.6 %
Total 340/23.4 % 1,116/76.6 % 1,456/100 %
HR HC2 Digene Hybrid Capture 2 High-Risk HPV DNA test, RT Abbott RealTime
High Risk HPV Test
Fig. 2 Prevalence of HR HPV detected by HC2 and RT; and HPV 16
and HPV 18 genotyping by RT
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types), while another 21 samples (44.7 %) were false-
negative by RT hrHPV revealing an unusually high false-
negative rate for the RT hrHPV test. These 21 samples
also included two specimens with CIN3+ histology. Both
samples were found to be positive for high risk HPV
type 31 by LiPA Extra genotyping with a total of six
CIN3+ samples positive for this HPV type.
The RT hrHPV test concurrently detects 14 different
HPV types and generates genotyping information for
specific identification of the highly carcinogenic types
HPV 16 and 18. The association of HPV 16 and HPV 18
with different cytology outcome as detected by RT
hrHPV is shown in Fig. 2. The overall detection rate for
HPV 16 (6.8 %) was higher than that of HPV 18 (1.0 %).
Prevalence of HPV 16 and 18 increases proportionally
with higher grade of cytology abnormalities and was
highest in HSIL and CIS (≥Pap IVa). 58.5 % of these
samples were positive for HPV 16 and 12.2 % for HPV
18. In contrast HPV 16 prevalence was 2.2 % compared
to 0.2 % for HPV18 in the normal (Pap I/II) and 3.6 %
versus 0 %, respectively, in the ASC-US (Pap IIw) cat-
egory. HPV 16 and HPV 18 were both detected in 6.3 %
of the specimens with ASC-H, AGC (Pap III) cytology
results in contrast to the LSIL, HSIL (Pap IIID) category,
which included 19.9 % HPV 16 positive and 2.3 % HPV
18 positive samples. All samples with a histology result
of CIN3+ were genotyped by using the INNO-LiPA
HPV Genotyping Extra test. Overall HR HPV genotype
distribution in specimens with CIN3+ lesions is shown
in Fig. 3. All HPV types detected in both single and mul-
tiple infections were included in the calculations. Not
surprisingly, HPV 16 (46.2 %) was the most prevalent
genotype in specimens with CIN3+ lesions followed by
HPV 31 (12.3 %), HPV 52 (9.2 %), HPV 33 (6.2 %) and
HPV 18 (4.6 %). All specimens with a LiPA Extra geno-
typing result of either HPV 16 or HPV18 were correctly
identified by the concurrent Abbott RT HPV 16/18
genotyping.
Sensitivity and specificity
Relative sensitivity and specificity were calculated to de-
fine the diagnostic accuracy of the HR HC2 and the RT
hrHPV test for detection of CIN3+. Within this cohort
81 biopsies were available from patients with abnormal
cytology results. Overall relative sensitivity for detection
of CIN3+ in patients with abnormal cytology was 93.8 %
Table 3 HPV genotyping of discordant samples with the LiPA Extra test
HPV Genotype HPV classification HC2-ve RT + ve (N) RT-ve HC2 + ve (N) Histology CIN3+ (HC2-ve/RT-ve)
HPV 16a HR 2 1 0
HPV 18a HR 0 3 0
HPV 31a HR 0 6 0/2
HPV 33a HR 0 0 0
HPV 39a HR 0 1 0
HPV 45a HR 2 0 0
HPV 51a HR 4 3 0
HPV 52a HR 0 4 0
HPV 56a HR 0 1 0
HPV 58a HR 0 1 0
HPV 59a HR 1 0 0
HPV 68a HR 0 0 0
HPV 53 Intermediate 0 11 0
HPV 66b Intermediate 0 1 0
HPV 70 Intermediate 0 2 0
HPV 6 LR 0 1 0
HPV 54 LR 0 1 0
HPV 74 1 1 0
HPVX 0 2 0




Total 18 47 0/2
a HC2 and RT target types; b RT target type; HC2, Digene Hybrid Capture 2 High-Risk HPV DNA test, RT, Abbott RealTime High Risk HPV Test, HPVX HPV DNA was
detected by LiPA, but could not be correlated to a specific type; HR High-risk, LR Low-risk; +ve: positive; −ve: negative; +: and worse
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for the Abbott RealTime hrHPV assay and 97.9 % for
HC2, a difference which is insignificant (p-value = 0.5;
Table 4). Similar results were obtained for the endpoint
CIN2+ (94.7 % vs 98.2 % respectively). Relative specific-
ities and positive predictive values (PPV) were compar-
able 81.1 % and 16.9 % for RT hrHPV and 79.8 % and
16.5 % for HC2, respectively. The PPV for the detection
of CIN2+ was highest at 84.2 % for the separate detec-
tion of HPV 16 by RT hrHPV. Overall 50 histology re-
views were performed. Sensitivity and specificity results
for the performances of both HPV tests with endpoint
CIN3+ did not change when the review results were
accounted for in the respective calculations (data not
shown).
Colposcopy was given only to women with abnormal
cytology findings; therefore the true number of high
grade CIN in the normal (Pap I/II) and ASC-US (Pap
IIw) categories is not known. Due to this lack of defini-
tive data one could not calculate the clinical sensitivity
and specificity of the two tests. However, we calculated
the ratio of the sensitivity and specificity of the two tests
to each other, thus we are able to determine relative, if
not absolute, performance. The ratio of sensitivities be-
tween RT hrHPV test and HC2 is 0.959 (95%CI: 0.885–
1.033). Fig. 4 shows the ratio of specificity as a function
of prevalence. We found no statistical difference be-
tween clinical sensitivity and specificity of the RT hrHPV
test and HC2 for the detection of high grade disease at
the 95 % confidence level.
Discussion
This study was conducted to evaluate the analytical and
relative performance of the RT hrHPV test using re-
sidual LBC specimens selected from a German routine
cervical cancer screening population. HR HPV positivity
rates overall (23.4 % for HC2 and 21.4 % for RT hrHPV)
and in LBC normal samples (5.4 % for RT hrHPV and
5.6 % for HC2) were in line with previously published
data [21]. HPV prevalence in women with abnormal cy-
tology (AGC+ ≥ PapIII) was 68 % detected by RT and
71.3 % for the HC2 test. The generally slightly higher de-
tection rates of the HC2 test may be attributed to cross-
reactivity with non-target types [27]. The most prevalent
HPV type in women with high grade cervical disease in
this study was HPV 16, which is in accordance with all
recent studies and meta-analyses (summarized by [28]).
Comparing the performances of both tests we showed
that the RT hrHPV and HC2 test performed similarly and
the agreement of both assays was excellent (κ = 0.87). These
results reflect previously reported data [13, 19, 21] and indi-
cate that both HPV DNA tests performed equivalently.
Table 4 Test characteristics of the RT hrHPV and HC2 tests for detection of high grade cervical disease (CIN3+)
Relative sensitivity CIN2+ Relative sensitivity CIN3+ Relative specificity <CIN2 PPV CIN2+ NPV < CIN2
% 95 % CI % 95 % CI % 95 % CI % 95 % CI % 95 % CI
HR HC2 98.2 89.4–99.9 97.9 97.5–99.9 79.8 77.5–81.8 16.5 12.8–21.0 99.9 99.4–100
Abbott RT 94.7 84.5–98.6 93.8 81.8–98.4 81.1 78.9–83.1 16.9 13.1–21.6 99.7 99.2–99.9
Abbott RT HPV16 56.1 42.4–66.9 60.4 45.3–73.9 75.0 52.9–89.4 84.2 59.4–68.1 41.9 27.4–57.8
Abbott RT HPV18 7.0 2.3–17.8 6.3 1.6–18.2 77.5 75.2–79.6 50 17.4–82.6 27.4 17.9–39.3
Abbott RT non 16/18 33.3 21.7–47.2 29.2 17.4–44.3 54.2 33.2–73.8 63.3 43.9–79.5 25.5 14.8–39.9
+: and worse; CI Confidence interval
Fig. 3 HPV genotype distribution in specimens with high grade
cervical disease (CIN3+)
Fig. 4 Specificity ratio of RT hrHPV and HC2 as a function of HR HPV
prevalence (green line: lower confidence interval boundary; red line:
upper boundary)
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Discordant samples were analyzed by the LiPA HPV geno-
typing Extra test, which has been used as an adjudicating
assay in test comparison studies before [24, 29, 30], due to
its high analytical sensitivity [31]. We found that 50 % of
HC2-negative, but RT hrHPV-positive samples were true
HPV negative. The possibility of false-negative HC2 results
has previously been reported to be attributed to a low viral
copy number leading to false-negative HC2 results [32] or
to the lack of an internal control for cellularity, which is
however ruled out here by the split sample protocol. Fur-
thermore, we found that the HC2 test was able to detect in-
fections with the non-target type HPV 53. Cross-reactivity
of the HC2 test with HPV 53 has been demonstrated by
multiple previous reports. In fact, HPV 53 has been shown
to be one of the most frequent non-target types detected by
the HC2 test through cross-hybridization of its HR probe
[21, 33–35]. While the HC2 test detected all cases of CIN3
+, the RT hrHPV test missed two CIN3+ cases positive for
HPV 31. Similar results have previously been published by
Poljak et al., who reported that the RT hrHPV test missed
two CIN3 + −cases with HPV 31 and 58 co-infections [36].
Two other reports also demonstrated a diminished sensitiv-
ity of the RT hrHPV test for HPV 31-positive CIN3 cases
[21, 30]. Indeed in the present study we found that one of
the two CIN3+ cases missed by RT hrHPV test represented
a co-infection with HPV-type 33, which might indicate
competitive primer binding in the PCR leading to an un-
favorable kinetic of amplification for HPV 31 or other types
from the alpha-9 subgenus in mixed infections.
Comparing concurrent genotyping results of the RT
hrHPV test we were able to show that RT HPV 16/18
genotyping correctly identified all specimens with a LiPA
Extra genotyping result of either HPV 16 or HPV 18.
These results are in contrast with earlier reports show-
ing concordance between LiPA and RT genotyping in
only 90 % of the tested specimens [10].
Relative sensitivities for detection of CIN3+ were high
and comparable for both tests (p-value = 0.5) whereas
relative specificities for RT was slightly higher than for the
HR HC2 test. By calculating the ratios of sensitivities and
specificities, respectively, we were able to confirm that no
statistical difference exists between the two tests’ perfor-
mances. Our observations are in line with cross-sectional
studies reported previously in routine screening popula-
tions [19–21] and suggest that RT hrHPV test is well
suited to be used in routine primary cervical cancer
screening or adjunctive to cytology. Further evidence for
the applicability of the RT hrHPV test in primary screen-
ing has recently been published by Poljak et al., reporting
the first longitudinal data for the Abbott RT HPV test
[23]. The authors demonstrated the non-inferior clinical
performance of the RT HPV test in a routine screening
population of 3,920 women with a 3-year follow-up time
in comparison to the performance of the HC2 test.
In summary we found that the sensitivities and relative
specificities of the RT hrHPV and the HR HC2 test are
comparable. However, it appears that the RT hrHPV test
has a reduced sensitivity for the detection of HPV type
31, which in this study has led to two CIN3+ cases
missed by the RT hrHPV test. Because HPV 31 is one of
the most prevalent high-risk HPV-types worldwide [37]
and is found in 3,5 % of global cervical cancer cases
[38], it is important to carefully assess risks and benefits
of applying the RT hrHPV test. A considerable benefit of
the RT hrHPV HPV test is its separate type specific de-
tection of the most prevalent HPV genotypes 16 and 18,
which together account for a total of an estimated
70.4 % of cervical cancer cases worldwide [38]; and we
demonstrated that the PPV for detecting high grade dis-
ease is by far highest for Abbott RT hrHPV HPV 16.
Conclusions
We provided evidence that the Abbott HR HPV test is
suitable for primary routine screening in Germany and
other countries with a similar infrastructure regarding
the secondary prevention of cervical cancer.
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